25 XP   0   0   10

Evogene
Buy, Hold or Sell?

Let's analyse Evogene together

PenkeI guess you are interested in Evogene. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Evogene. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Evogene

I send you an email if I find something interesting about Evogene.

Quick analysis of Evogene (30 sec.)










What can you expect buying and holding a share of Evogene? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.65
Expected worth in 1 year
$0.75
How sure are you?
15.0%

+ What do you gain per year?

Total Gains per Share
$0.09
Return On Investment
12.2%

For what price can you sell your share?

Current Price per Share
$0.75
Expected price per share
$0.6473 - $1.04
How sure are you?
50%

1. Valuation of Evogene (5 min.)




Live pricePrice per Share (EOD)

$0.75

Intrinsic Value Per Share

$-5.07 - $-1.71

Total Value Per Share

$-4.41 - $-1.05

2. Growth of Evogene (5 min.)




Is Evogene growing?

Current yearPrevious yearGrowGrow %
How rich?$33.1m$41.7m-$9.5m-29.8%

How much money is Evogene making?

Current yearPrevious yearGrowGrow %
Making money-$6.1m-$7.4m$1.3m21.4%
Net Profit Margin-852.7%-2,271.1%--

How much money comes from the company's main activities?

3. Financial Health of Evogene (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#535 / 1031

Most Revenue
#466 / 1031

Most Profit
#499 / 1031

Most Efficient
#807 / 1031

What can you expect buying and holding a share of Evogene? (5 min.)

Welcome investor! Evogene's management wants to use your money to grow the business. In return you get a share of Evogene.

What can you expect buying and holding a share of Evogene?

First you should know what it really means to hold a share of Evogene. And how you can make/lose money.

Speculation

The Price per Share of Evogene is $0.75. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Evogene.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Evogene, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.65. Based on the TTM, the Book Value Change Per Share is $0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.17 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Evogene.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.13-17.4%-0.12-16.2%-0.13-17.5%-0.12-15.9%-0.13-16.7%
Usd Book Value Change Per Share-0.05-7.2%0.023.0%-0.17-23.0%-0.02-2.3%-0.05-6.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.05-7.2%0.023.0%-0.17-23.0%-0.02-2.3%-0.05-6.0%
Usd Price Per Share0.84-0.78-0.90-1.84-4.55-
Price to Earnings Ratio-1.61--1.64--1.91--4.02--10.80-
Price-to-Total Gains Ratio-15.45-3.84--5.32-16.96--41.05-
Price to Book Ratio1.28-1.24-1.10-1.76-2.73-
Price-to-Total Gains Ratio-15.45-3.84--5.32-16.96--41.05-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.75
Number of shares1333
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.02-0.02
Usd Total Gains Per Share0.02-0.02
Gains per Quarter (1333 shares)30.39-22.64
Gains per Year (1333 shares)121.55-90.55
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101221120-91-101
202432340-181-192
303653560-272-283
404864780-362-374
506086000-453-465
607297220-543-556
708518440-634-647
809729660-724-738
90109410880-815-829
100121512100-906-920

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%3.045.00.06.3%
Book Value Change Per Share2.01.01.050.0%3.07.02.025.0%6.010.04.030.0%6.026.08.015.0%11.029.08.022.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.048.00.0%
Total Gains per Share2.01.01.050.0%3.07.02.025.0%6.010.04.030.0%6.026.08.015.0%11.029.08.022.9%

Fundamentals of Evogene

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Fundamental data was last updated by Penke on 2024-03-20 16:33:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Evogene.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Evogene earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Evogene to the Biotechnology industry mean.
  • A Net Profit Margin of -1,142.0% means that $-11.42 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Evogene:

  • The MRQ is -1,142.0%. The company is making a huge loss. -2
  • The TTM is -852.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,142.0%TTM-852.7%-289.4%
TTM-852.7%YOY-2,271.1%+1,418.5%
TTM-852.7%5Y-2,497.8%+1,645.2%
5Y-2,497.8%10Y-1,496.1%-1,001.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,142.0%-159.2%-982.8%
TTM-852.7%-202.3%-650.4%
YOY-2,271.1%-263.0%-2,008.1%
5Y-2,497.8%-452.4%-2,045.4%
10Y-1,496.1%-589.0%-907.1%
1.1.2. Return on Assets

Shows how efficient Evogene is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Evogene to the Biotechnology industry mean.
  • -12.9% Return on Assets means that Evogene generated $-0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Evogene:

  • The MRQ is -12.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.9%TTM-11.8%-1.1%
TTM-11.8%YOY-12.7%+0.9%
TTM-11.8%5Y-10.0%-1.7%
5Y-10.0%10Y-7.7%-2.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.9%-12.5%-0.4%
TTM-11.8%-12.2%+0.4%
YOY-12.7%-11.2%-1.5%
5Y-10.0%-13.3%+3.3%
10Y-7.7%-14.6%+6.9%
1.1.3. Return on Equity

Shows how efficient Evogene is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Evogene to the Biotechnology industry mean.
  • -54.8% Return on Equity means Evogene generated $-0.55 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Evogene:

  • The MRQ is -54.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -39.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-54.8%TTM-39.3%-15.5%
TTM-39.3%YOY-21.8%-17.5%
TTM-39.3%5Y-19.5%-19.8%
5Y-19.5%10Y-12.7%-6.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-54.8%-16.0%-38.8%
TTM-39.3%-15.8%-23.5%
YOY-21.8%-13.9%-7.9%
5Y-19.5%-18.2%-1.3%
10Y-12.7%-19.1%+6.4%

1.2. Operating Efficiency of Evogene.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Evogene is operating .

  • Measures how much profit Evogene makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Evogene to the Biotechnology industry mean.
  • An Operating Margin of -1,319.7% means the company generated $-13.20  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Evogene:

  • The MRQ is -1,319.7%. The company is operating very inefficient. -2
  • The TTM is -907.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,319.7%TTM-907.0%-412.7%
TTM-907.0%YOY-2,015.3%+1,108.3%
TTM-907.0%5Y-2,516.6%+1,609.6%
5Y-2,516.6%10Y-1,488.6%-1,028.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,319.7%-299.5%-1,020.2%
TTM-907.0%-208.5%-698.5%
YOY-2,015.3%-280.2%-1,735.1%
5Y-2,516.6%-459.9%-2,056.7%
10Y-1,488.6%-596.9%-891.7%
1.2.2. Operating Ratio

Measures how efficient Evogene is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 14.20 means that the operating costs are $14.20 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Evogene:

  • The MRQ is 14.197. The company is inefficient in keeping operating costs low. -1
  • The TTM is 10.248. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ14.197TTM10.248+3.950
TTM10.248YOY21.153-10.905
TTM10.2485Y27.772-17.525
5Y27.77210Y16.828+10.945
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.1972.817+11.380
TTM10.2483.181+7.067
YOY21.1533.609+17.544
5Y27.7725.554+22.218
10Y16.8287.396+9.432

1.3. Liquidity of Evogene.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Evogene is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.96 means the company has $4.96 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Evogene:

  • The MRQ is 4.964. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.668. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.964TTM5.668-0.704
TTM5.668YOY6.888-1.220
TTM5.6685Y7.929-2.261
5Y7.92910Y12.204-4.275
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9643.987+0.977
TTM5.6684.440+1.228
YOY6.8885.569+1.319
5Y7.9296.158+1.771
10Y12.2046.492+5.712
1.3.2. Quick Ratio

Measures if Evogene is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Evogene to the Biotechnology industry mean.
  • A Quick Ratio of 6.01 means the company can pay off $6.01 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Evogene:

  • The MRQ is 6.007. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.646. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.007TTM5.646+0.361
TTM5.646YOY8.010-2.365
TTM5.6465Y10.188-4.542
5Y10.18810Y20.478-10.291
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.0073.653+2.354
TTM5.6464.158+1.488
YOY8.0105.515+2.495
5Y10.1886.012+4.176
10Y20.4786.206+14.272

1.4. Solvency of Evogene.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Evogene assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Evogene to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.35 means that Evogene assets are financed with 35.2% credit (debt) and the remaining percentage (100% - 35.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Evogene:

  • The MRQ is 0.352. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.393. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.352TTM0.393-0.041
TTM0.393YOY0.290+0.103
TTM0.3935Y0.235+0.158
5Y0.23510Y0.164+0.071
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3520.336+0.016
TTM0.3930.330+0.063
YOY0.2900.267+0.023
5Y0.2350.367-0.132
10Y0.1640.378-0.214
1.4.2. Debt to Equity Ratio

Measures if Evogene is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Evogene to the Biotechnology industry mean.
  • A Debt to Equity ratio of 149.3% means that company has $1.49 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Evogene:

  • The MRQ is 1.493. The company is able to pay all its debts with equity. +1
  • The TTM is 1.295. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.493TTM1.295+0.197
TTM1.295YOY0.553+0.742
TTM1.2955Y0.509+0.786
5Y0.50910Y0.306+0.203
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4930.376+1.117
TTM1.2950.398+0.897
YOY0.5530.334+0.219
5Y0.5090.431+0.078
10Y0.3060.476-0.170

2. Market Valuation of Evogene

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Evogene generates.

  • Above 15 is considered overpriced but always compare Evogene to the Biotechnology industry mean.
  • A PE ratio of -1.61 means the investor is paying $-1.61 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Evogene:

  • The EOD is -1.438. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.610. Based on the earnings, the company is expensive. -2
  • The TTM is -1.636. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.438MRQ-1.610+0.173
MRQ-1.610TTM-1.636+0.025
TTM-1.636YOY-1.913+0.277
TTM-1.6365Y-4.016+2.380
5Y-4.01610Y-10.803+6.787
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.438-2.697+1.259
MRQ-1.610-2.422+0.812
TTM-1.636-2.709+1.073
YOY-1.913-4.116+2.203
5Y-4.016-6.257+2.241
10Y-10.803-6.478-4.325
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Evogene:

  • The EOD is -1.653. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.851. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.823. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.653MRQ-1.851+0.198
MRQ-1.851TTM-1.823-0.028
TTM-1.823YOY-2.117+0.294
TTM-1.8235Y-4.420+2.596
5Y-4.42010Y-21.931+17.511
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.653-3.344+1.691
MRQ-1.851-2.939+1.088
TTM-1.823-3.486+1.663
YOY-2.117-5.592+3.475
5Y-4.420-8.464+4.044
10Y-21.931-8.872-13.059
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Evogene is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.28 means the investor is paying $1.28 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Evogene:

  • The EOD is 1.147. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.284. Based on the equity, the company is underpriced. +1
  • The TTM is 1.243. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.147MRQ1.284-0.138
MRQ1.284TTM1.243+0.041
TTM1.243YOY1.100+0.143
TTM1.2435Y1.765-0.521
5Y1.76510Y2.730-0.965
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.1472.198-1.051
MRQ1.2842.042-0.758
TTM1.2432.121-0.878
YOY1.1002.907-1.807
5Y1.7653.682-1.917
10Y2.7304.114-1.384
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Evogene.

3.1. Institutions holding Evogene

Institutions are holding 8.912% of the shares of Evogene.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31SILVERARC CAPITAL MANAGEMENT, LLC6.12370.7751310000000
2023-12-31Walleye Trading Advisors, LLC0.69030.0006349477-167615-32.4149
2023-12-31Morgan Stanley - Brokerage Accounts0.37230188446126317.1843
2023-12-31BNP Paribas Arbitrage, SA0.13810.00016990040006.0698
2023-12-31LPL Financial Corp0.13206683500
2023-12-31JPMorgan Chase & Co0.12760645942933683.2038
2023-12-31Geode Capital Management, LLC0.116605900700
2023-12-31UBS Group AG0.11060560052000055.5478
2023-12-31Renaissance Technologies Corp0.08850.000144800-600-1.3216
2023-09-30PNC Financial Services Group Inc0.0711036000360000
2023-12-31Millennium Management LLC0.067303407420426149.663
2023-12-31Csenge Advisory Group, LLC0.06080.00163076200
2023-12-31Joel Isaacson & CO., LLC0.05990.00163030000
2023-09-30Citadel Advisors Llc0.054302748815391127.2299
2023-12-31Susquehanna International Group, LLP0.0481024330243300
2023-12-31Sigma Planning Corp0.04560.001523087-27898-54.7181
2023-12-31Private Advisor Group, LLC0.02770.00011401300
2023-12-31TWO SIGMA SECURITIES, LLC0.02440.000112373-2319-15.7841
2023-12-31Malaga Cove Capital, LLC0.02370.00431200000
2023-12-31SNS Financial Group, LLC0.01980.0011000000
Total 8.40240.78614253491-36318-0.9%

3.2. Funds holding Evogene

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31P & S Renditefonds T0.19750.266310000000
2023-11-30MTF TR TA-Growth0.18461.84369345970109300.2527
2023-09-22Medical Cannabis and Wellness ETF Acc0.1370.519669359-34567-33.2612
2024-01-31Fidelity Nasdaq Composite Index0.11660.00035900700
2023-05-31I.B.I Cannabis Israel Related0.05297.721226801-1026-3.6871
2023-11-30Psagot ETF TA-Growth0.04781.84382420117763275.9087
2023-11-30Alfi Benedek Israel Equities0.0410.23732076000
2023-11-30Impact Stocks IL0.03120.11021581400
2023-11-30Harel HTF TA All-Share IL0.01610.284581595249180.378
2023-11-30Sigma 70/30 IL0.00030.000413800
2023-11-30Sigma Bond Portfolio + 15% IL00100
Total 0.82512.8272417699+57528+13.8%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Evogene compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0540.023-338%-0.172+217%-0.017-69%-0.045-17%
Book Value Per Share--0.6540.635+3%0.824-21%0.994-34%1.408-54%
Current Ratio--4.9645.668-12%6.888-28%7.929-37%12.204-59%
Debt To Asset Ratio--0.3520.393-10%0.290+21%0.235+50%0.164+115%
Debt To Equity Ratio--1.4931.295+15%0.553+170%0.509+193%0.306+388%
Dividend Per Share----0%-0%-0%-0%
Eps---0.130-0.121-7%-0.132+1%-0.119-9%-0.125-4%
Free Cash Flow Per Share---0.113-0.109-4%-0.123+8%-0.109-4%-0.089-21%
Free Cash Flow To Equity Per Share---0.118-0.020-83%-0.077-35%-0.039-67%-0.013-89%
Gross Profit Margin--1.0001.115-10%1.076-7%1.038-4%1.019-2%
Intrinsic Value_10Y_max---1.707--------
Intrinsic Value_10Y_min---5.067--------
Intrinsic Value_1Y_max---0.330--------
Intrinsic Value_1Y_min---0.497--------
Intrinsic Value_3Y_max---0.870--------
Intrinsic Value_3Y_min---1.512--------
Intrinsic Value_5Y_max---1.265--------
Intrinsic Value_5Y_min---2.539--------
Market Cap37967475.000-12%42523572.00039568436.863+7%45560970.000-7%93263811.823-54%230182246.726-82%
Net Profit Margin---11.420-8.527-25%-22.711+99%-24.978+119%-14.961+31%
Operating Margin---13.197-9.070-31%-20.153+53%-25.166+91%-14.886+13%
Operating Ratio--14.19710.248+39%21.153-33%27.772-49%16.828-16%
Pb Ratio1.147-12%1.2841.243+3%1.100+17%1.765-27%2.730-53%
Pe Ratio-1.438+11%-1.610-1.636+2%-1.913+19%-4.016+149%-10.803+571%
Price Per Share0.750-12%0.8400.782+7%0.900-7%1.842-54%4.547-82%
Price To Free Cash Flow Ratio-1.653+11%-1.851-1.823-2%-2.117+14%-4.420+139%-21.931+1085%
Price To Total Gains Ratio-13.796+11%-15.4523.838-503%-5.321-66%16.958-191%-41.052+166%
Quick Ratio--6.0075.646+6%8.010-25%10.188-41%20.478-71%
Return On Assets---0.129-0.118-9%-0.127-2%-0.100-22%-0.077-40%
Return On Equity---0.548-0.393-28%-0.218-60%-0.195-64%-0.127-77%
Total Gains Per Share---0.0540.023-338%-0.172+217%-0.017-69%-0.045-17%
Usd Book Value--33111000.00032144500.000+3%41730250.000-21%50343100.000-34%71287100.000-54%
Usd Book Value Change Per Share---0.0540.023-338%-0.172+217%-0.017-69%-0.045-17%
Usd Book Value Per Share--0.6540.635+3%0.824-21%0.994-34%1.408-54%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.130-0.121-7%-0.132+1%-0.119-9%-0.125-4%
Usd Free Cash Flow---5741807.000-5523201.750-4%-6212250.000+8%-5493190.350-4%-4509295.175-21%
Usd Free Cash Flow Per Share---0.113-0.109-4%-0.123+8%-0.109-4%-0.089-21%
Usd Free Cash Flow To Equity Per Share---0.118-0.020-83%-0.077-35%-0.039-67%-0.013-89%
Usd Market Cap37967475.000-12%42523572.00039568436.863+7%45560970.000-7%93263811.823-54%230182246.726-82%
Usd Price Per Share0.750-12%0.8400.782+7%0.900-7%1.842-54%4.547-82%
Usd Profit---6601000.000-6147250.000-7%-7461000.000+13%-6358700.000-4%-5682375.000-14%
Usd Revenue--578000.0001410000.000-59%418750.000+38%519200.000+11%1252325.000-54%
Usd Total Gains Per Share---0.0540.023-338%-0.172+217%-0.017-69%-0.045-17%
 EOD+3 -5MRQTTM+9 -25YOY+15 -195Y+6 -2810Y+6 -28

4.2. Fundamental Score

Let's check the fundamental score of Evogene based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.438
Price to Book Ratio (EOD)Between0-11.147
Net Profit Margin (MRQ)Greater than0-11.420
Operating Margin (MRQ)Greater than0-13.197
Quick Ratio (MRQ)Greater than16.007
Current Ratio (MRQ)Greater than14.964
Debt to Asset Ratio (MRQ)Less than10.352
Debt to Equity Ratio (MRQ)Less than11.493
Return on Equity (MRQ)Greater than0.15-0.548
Return on Assets (MRQ)Greater than0.05-0.129
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Evogene based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.780
Ma 20Greater thanMa 500.838
Ma 50Greater thanMa 1000.816
Ma 100Greater thanMa 2000.781
OpenGreater thanClose0.728
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Gross Profit  29623319-1261933,0633,256-3,739-483



Latest Balance Sheet

Balance Sheet of 2023-12-31. All numbers in thousands.

Summary
Total Assets51,101
Total Liabilities17,990
Total Stockholder Equity12,053
 As reported
Total Liabilities 17,990
Total Stockholder Equity+ 12,053
Total Assets = 51,101

Assets

Total Assets51,101
Total Current Assets34,469
Long-term Assets16,632
Total Current Assets
Cash And Cash Equivalents 20,772
Short-term Investments 10,291
Net Receivables 357
Inventory 76
Other Current Assets 2,973
Total Current Assets  (as reported)34,469
Total Current Assets  (calculated)34,469
+/-0
Long-term Assets
Property Plant Equipment 3,435
Long-term Assets Other 13,197
Long-term Assets  (as reported)16,632
Long-term Assets  (calculated)16,632
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities6,944
Long-term Liabilities11,046
Total Stockholder Equity12,053
Total Current Liabilities
Short-term Debt 853
Accounts payable 1,785
Other Current Liabilities 3,944
Total Current Liabilities  (as reported)6,944
Total Current Liabilities  (calculated)6,582
+/- 362
Long-term Liabilities
Long-term Liabilities  (as reported)11,046
Long-term Liabilities  (calculated)0
+/- 11,046
Total Stockholder Equity
Common Stock286
Retained Earnings -257,586
Other Stockholders Equity 269,353
Total Stockholder Equity (as reported)12,053
Total Stockholder Equity (calculated)12,053
+/-0
Other
Cash and Short Term Investments 31,063
Common Stock Shares Outstanding 50,585
Current Deferred Revenue362
Liabilities and Stockholders Equity 51,101
Net Debt -19,634
Net Working Capital 27,525
Short Long Term Debt Total 1,138



Balance Sheet

All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
67,890
0
65,376
63,549
64,855
63,179
62,004
59,665
137,311
137,311
131,856
129,763
127,586
127,586
119,863
116,366
112,595
112,595
105,934
101,785
95,986
95,986
87,446
83,105
77,602
72,049
68,090
63,666
58,694
58,694
53,454
76,443
71,364
71,364
61,106
65,985
71,915
71,915
87,537
83,389
76,304
66,881
56,662
59,388
49,475
49,475
53,340
57,746
51,101
51,10157,74653,34049,47549,47559,38856,66266,88176,30483,38987,53771,91571,91565,98561,10671,36471,36476,44353,45458,69458,69463,66668,09072,04977,60283,10587,44695,98695,986101,785105,934112,595112,595116,366119,863127,586127,586129,763131,856137,311137,31159,66562,00463,17964,85563,54965,376067,890
   > Total Current Assets 
0
0
57,393
55,814
57,322
55,414
53,967
51,919
129,552
129,552
114,155
111,235
118,371
118,371
111,823
108,398
104,376
104,376
98,564
94,942
89,490
89,490
81,821
77,842
72,791
67,655
64,083
60,013
55,488
55,488
47,795
53,828
49,027
49,027
39,844
45,392
51,823
51,823
67,867
63,600
56,890
47,628
37,705
40,772
31,409
31,409
35,720
40,555
34,469
34,46940,55535,72031,40931,40940,77237,70547,62856,89063,60067,86751,82351,82345,39239,84449,02749,02753,82847,79555,48855,48860,01364,08367,65572,79177,84281,82189,49089,49094,94298,564104,376104,376108,398111,823118,371118,371111,235114,155129,552129,55251,91953,96755,41457,32255,81457,39300
       Cash And Cash Equivalents 
6,465
0
22,158
23,613
24,262
19,369
16,884
16,655
95,454
95,454
8,716
14,962
5,213
5,213
7,949
11,847
10,221
10,221
5,533
5,439
3,236
3,236
5,758
2,457
3,435
5,353
14,731
5,710
5,810
5,810
14,097
16,467
34,748
34,748
31,074
41,494
46,229
46,229
42,755
37,633
32,325
36,013
28,867
31,860
23,000
23,000
20,233
27,331
20,772
20,77227,33120,23323,00023,00031,86028,86736,01332,32537,63342,75546,22946,22941,49431,07434,74834,74816,46714,0975,8105,8105,71014,7315,3533,4352,4575,7583,2363,2365,4395,53310,22110,22111,8477,9495,2135,21314,9628,71695,45495,45416,65516,88419,36924,26223,61322,15806,465
       Short-term Investments 
52,324
0
30,643
30,260
30,868
33,168
33,657
31,684
31,452
31,452
102,549
93,850
110,086
110,086
102,040
94,458
90,410
90,410
91,362
87,578
84,875
84,875
73,895
73,399
68,320
60,590
47,540
52,501
48,657
48,657
31,680
35,654
12,128
12,128
7,000
2,000
2,000
2,000
22,609
23,960
21,541
8,545
6,383
6,090
5,795
5,795
13,641
9,896
10,291
10,2919,89613,6415,7955,7956,0906,3838,54521,54123,96022,6092,0002,0002,0007,00012,12812,12835,65431,68048,65748,65752,50147,54060,59068,32073,39973,89584,87584,87587,57891,36290,41090,41094,458102,040110,086110,08693,850102,54931,45231,45231,68433,65733,16830,86830,26030,643052,324
       Net Receivables 
0
0
4,592
1,941
1,542
2,877
3,426
3,580
2,646
2,646
2,890
2,423
2,072
2,072
1,834
2,046
3,698
3,698
1,622
1,878
1,332
1,332
2,121
1,939
989
1,712
1,812
1,802
1,021
1,021
2,018
1,707
2,151
2,151
1,770
1,898
3,594
3,594
2,503
2,007
2,932
2,898
2,293
2,657
2,023
250
1,597
3,215
357
3573,2151,5972502,0232,6572,2932,8982,9322,0072,5033,5943,5941,8981,7702,1512,1511,7072,0181,0211,0211,8021,8121,7129891,9392,1211,3321,3321,8781,6223,6983,6982,0461,8342,0722,0722,4232,8902,6462,6463,5803,4262,8771,5421,9414,59200
       Inventory 
0
0
0
0
0
0
0
0
-733
-733
0
0
-29,046
-29,046
0
-14,544
-18,556
-18,556
-16,514
-15,011
-13,090
-13,090
-7,970
-9,470
-8,333
0
0
0
-444
-444
0
0
-1,174
-1,174
0
0
-1,562
-1,562
0
0
92
172
162
165
591
591
249
113
76
761132495915911651621729200-1,562-1,56200-1,174-1,17400-444-444000-8,333-9,470-7,970-13,090-13,090-15,011-16,514-18,556-18,556-14,5440-29,046-29,04600-733-73300000000
   > Long-term Assets 
0
0
7,983
7,735
7,533
7,765
8,037
7,746
7,759
7,759
17,701
18,528
9,215
9,215
8,040
7,968
8,219
8,219
7,370
6,843
6,496
6,496
5,625
5,263
4,811
4,394
4,007
3,653
3,206
3,206
5,659
22,615
22,337
22,337
21,262
20,593
20,092
20,092
19,670
19,789
19,414
19,253
18,957
18,616
18,066
18,066
17,620
17,191
16,632
16,63217,19117,62018,06618,06618,61618,95719,25319,41419,78919,67020,09220,09220,59321,26222,33722,33722,6155,6593,2063,2063,6534,0074,3944,8115,2635,6256,4966,4966,8437,3708,2198,2197,9688,0409,2159,21518,52817,7017,7597,7597,7468,0377,7657,5337,7357,98300
       Property Plant Equipment 
7,138
0
0
7,597
7,401
0
7,572
7,294
7,215
7,215
7,188
8,027
8,812
8,812
8,016
7,943
8,197
8,197
7,354
6,829
6,483
6,483
5,611
5,248
4,792
4,375
3,986
3,632
3,187
3,187
5,659
5,352
5,254
5,254
4,644
4,210
3,944
3,944
3,981
4,322
4,182
4,356
4,303
4,210
4,091
4,091
3,908
3,661
3,435
3,4353,6613,9084,0914,0914,2104,3034,3564,1824,3223,9813,9443,9444,2104,6445,2545,2545,3525,6593,1873,1873,6323,9864,3754,7925,2485,6116,4836,4836,8297,3548,1978,1977,9438,0168,8128,8128,0277,1887,2157,2157,2947,57207,4017,597007,138
       Long Term Investments 
0
0
0
0
0
0
0
365
471
0
0
0
382
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
0
0
0
0
0
0
0
0
0
0
0
00000000000100000000000000000000000003820004713650000000
       Intangible Assets 
134
0
111
100
89
78
67
56
45
45
22
11
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,255
17,074
17,074
0
0
16,139
16,139
0
0
15,207
0
0
0
14,140
0
0
0
0
000014,14000015,2070016,13916,1390017,07417,07417,255000000000000000000011224545566778891001110134
       Long-term Assets Other 
0
0
7,872
7,635
43
7,322
33
31
28
28
10,020
19
21
21
24
25
22
22
16
14
13
13
14
15
19
19
21
21
19
19
5,659
8
9
9
9
9
9
9
12
25
25
25
24
21
74
0
53
106
13,197
13,1971065307421242525251299999985,6591919212119191514131314162222252421211910,020282831337,322437,6357,87200
> Total Liabilities 
19,801
0
17,015
15,661
16,596
14,642
14,705
13,257
12,564
12,564
10,028
9,476
11,504
11,504
9,509
8,275
8,843
8,843
8,246
8,503
8,697
8,697
8,111
8,100
8,224
7,702
8,137
7,891
8,388
8,388
10,596
10,309
11,147
11,147
10,132
9,915
15,033
15,033
10,894
12,629
12,884
12,150
11,265
21,090
20,980
20,980
22,231
21,883
17,990
17,99021,88322,23120,98020,98021,09011,26512,15012,88412,62910,89415,03315,0339,91510,13211,14711,14710,30910,5968,3888,3887,8918,1377,7028,2248,1008,1118,6978,6978,5038,2468,8438,8438,2759,50911,50411,5049,47610,02812,56412,56413,25714,70514,64216,59615,66117,015019,801
   > Total Current Liabilities 
9,080
0
8,032
7,760
9,499
8,193
9,046
8,492
8,574
8,574
6,503
6,237
7,919
7,919
5,491
4,743
5,639
5,639
5,445
5,572
5,225
5,225
4,633
4,661
4,664
4,652
4,946
5,062
5,431
5,431
4,713
4,729
5,729
5,729
4,821
4,639
9,676
9,676
5,326
6,541
6,882
6,282
5,541
5,583
5,356
5,356
6,391
6,484
6,944
6,9446,4846,3915,3565,3565,5835,5416,2826,8826,5415,3269,6769,6764,6394,8215,7295,7294,7294,7135,4315,4315,0624,9464,6524,6644,6614,6335,2255,2255,5725,4455,6395,6394,7435,4917,9197,9196,2376,5038,5748,5748,4929,0468,1939,4997,7608,03209,080
       Short-term Debt 
0
0
1,866
1,891
2,406
2,224
2,677
2,945
3,738
3,738
2,840
2,954
3,284
3,284
2,485
2,428
2,790
2,790
1,729
2,015
2,678
2,678
2,399
2,595
2,830
1,630
1,753
1,624
2,028
2,028
716
960
895
895
829
789
777
777
785
927
974
966
754
884
904
0
894
854
853
85385489409048847549669749277857777777898298958959607162,0282,0281,6241,7531,6302,8302,5952,3992,6782,6782,0151,7292,7902,7902,4282,4853,2843,2842,9542,8403,7383,7382,9452,6772,2242,4061,8911,86600
       Short Long Term Debt 
0
0
0
1,891
0
0
0
2,945
0
0
0
0
3,854
0
0
0
3,049
0
0
0
2,803
0
0
0
2,934
0
0
0
0
673
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000067300002,9340002,8030003,0490003,85400002,9450001,891000
       Accounts payable 
2,059
0
1,299
1,052
1,416
1,266
1,873
1,461
2,014
2,014
1,488
1,849
1,984
1,984
1,205
1,021
1,771
1,771
1,364
1,071
1,330
1,330
947
898
1,110
911
1,048
784
1,015
1,015
748
820
1,001
1,001
718
701
863
863
1,203
1,850
1,463
1,346
1,324
977
1,152
1,152
1,078
1,176
1,785
1,7851,1761,0781,1521,1529771,3241,3461,4631,8501,2038638637017181,0011,0018207481,0151,0157841,0489111,1108989471,3301,3301,0711,3641,7711,7711,0211,2051,9841,9841,8491,4882,0142,0141,4611,8731,2661,4161,0521,29902,059
       Other Current Liabilities 
7,021
0
493
470
733
518
528
520
625
625
603
463
570
570
553
470
259
259
766
680
125
125
103
81
104
712
676
1,028
988
988
2,554
2,752
3,410
3,410
2,664
2,934
7,917
7,917
3,168
3,614
4,181
3,729
3,321
3,268
3,061
0
3,486
3,081
3,944
3,9443,0813,48603,0613,2683,3213,7294,1813,6143,1687,9177,9172,9342,6643,4103,4102,7522,5549889881,0286767121048110312512568076625925947055357057046360362562552052851873347049307,021
   > Long-term Liabilities 
0
0
8,983
7,901
7,097
6,449
5,659
4,765
3,990
3,990
3,525
3,239
3,585
3,585
4,018
3,532
3,204
3,204
2,801
2,931
3,472
3,472
3,478
3,439
3,560
3,050
3,191
2,829
2,957
2,957
5,883
5,580
5,418
5,418
5,311
5,276
5,357
5,357
5,568
6,088
6,002
5,868
5,724
15,507
15,624
15,624
15,840
15,399
11,046
11,04615,39915,84015,62415,62415,5075,7245,8686,0026,0885,5685,3575,3575,2765,3115,4185,4185,5805,8832,9572,9572,8293,1913,0503,5603,4393,4783,4723,4722,9312,8013,2043,2043,5324,0183,5853,5853,2393,5253,9903,9904,7655,6596,4497,0977,9018,98300
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,454
2,638
2,273
2,076
1,735
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000001,7352,0762,2732,6382,45400000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
-1,866
-1,891
-2,406
-2,224
-2,677
-2,945
-3,738
-3,738
-2,840
-2,954
-3,284
-3,284
-2,485
-2,428
-2,790
-2,790
-1,729
-2,015
-2,678
-2,678
-2,399
-2,595
-2,830
-1,630
-1,753
-1,624
-2,028
1,099
2,638
2,273
2,076
1,817
1,787
1,672
1,663
1,573
1,602
1,788
1,695
1,538
1,367
1,043
912
1,643
585
387
-853
-8533875851,6439121,0431,3671,5381,6951,7881,6021,5731,6631,6721,7871,8172,0762,2732,6381,099-2,028-1,624-1,753-1,630-2,830-2,595-2,399-2,678-2,678-2,015-1,729-2,790-2,790-2,428-2,485-3,284-3,284-2,954-2,840-3,738-3,738-2,945-2,677-2,224-2,406-1,891-1,86600
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,138
3,209
3,270
3,325
3,485
3,524
3,604
3,694
0
0
0
0
0
0
0
0
0
0
0
0
0000000000003,6943,6043,5243,4853,3253,2703,2093,13800000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
5,013
0
0
0
1,877
0
0
0
0
453
0
0
0
298
0
0
0
138
0
0
0
89
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000008900013800029800045300001,8770005,013000
> Total Stockholder Equity
48,089
0
48,361
47,888
48,259
48,537
47,299
46,408
124,747
124,747
121,828
120,287
116,082
116,082
110,354
108,091
103,752
103,752
97,688
93,282
87,289
87,289
79,335
75,005
69,378
64,347
59,953
55,502
50,053
50,053
42,588
56,090
50,144
50,144
39,762
44,930
46,045
46,045
66,401
60,692
54,031
45,531
36,949
30,577
22,089
22,089
14,288
18,510
12,053
12,05318,51014,28822,08922,08930,57736,94945,53154,03160,69266,40146,04546,04544,93039,76250,14450,14456,09042,58850,05350,05355,50259,95364,34769,37875,00579,33587,28987,28993,28297,688103,752103,752108,091110,354116,082116,082120,287121,828124,747124,74746,40847,29948,53748,25947,88848,361048,089
   Common Stock
100
0
100
101
102
102
103
103
137
137
138
139
140
140
140
140
140
140
140
140
141
141
142
142
142
142
142
142
142
142
142
142
142
142
142
177
200
200
231
234
234
234
234
234
237
0
237
286
286
28628623702372342342342342342312002001771421421421421421421421421421421421421421411411401401401401401401401401391381371371031031021021011000100
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
-5,599
0
1,156
1,156
1,156
1,156
0
0
-222
-222
0
0
-12,233
-12,233
0
0
-14,458
-14,458
0
0
-16,603
0
0
0
-18,623
-18,623
0
0
-20,948
-20,948
0
0
0
0
0
0
0
0
0
261,052
261,830
0
261,052
269,209
0
0269,209261,0520261,830261,052000000000-20,948-20,94800-18,623-18,623000-16,60300-14,458-14,45800-12,233-12,23300-222-222001,1561,1561,1561,1560-5,5990000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
187,701
187,884
188,039
205,772
205,904
205,964
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000205,964205,904205,772188,039187,884187,7010000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
82,455
83,003
89,737
84,897
84,383
85,791
168,313
168,313
172,077
174,714
175,553
175,553
177,962
179,081
192,447
192,447
181,985
182,693
197,800
197,800
184,977
185,671
202,871
186,623
186,998
187,349
206,324
206,324
188,039
205,772
226,852
226,852
205,990
215,907
225,121
225,121
258,258
260,156
260,866
260,641
260,880
261,052
0
0
261,052
269,209
269,353
269,353269,209261,05200261,052260,880260,641260,866260,156258,258225,121225,121215,907205,990226,852226,852205,772188,039206,324206,324187,349186,998186,623202,871185,671184,977197,800197,800182,693181,985192,447192,447179,081177,962175,553175,553174,714172,077168,313168,31385,79184,38384,89789,73783,00382,45500



Balance Sheet

All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue5,640
Cost of Revenue-4,304
Gross Profit1,3361,336
 
Operating Income (+$)
Gross Profit1,336
Operating Expense-27,844
Operating Income-26,508-26,508
 
Operating Expense (+$)
Research Development20,777
Selling General Administrative10,241
Selling And Marketing Expenses0
Operating Expense27,84431,018
 
Net Interest Income (+$)
Interest Income631
Interest Expense-965
Other Finance Cost-3,150
Net Interest Income2,816
 
Pretax Income (+$)
Operating Income-26,508
Net Interest Income2,816
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-25,987-27,029
EBIT - interestExpense = -27,473
-23,912
-22,914
Interest Expense965
Earnings Before Interest and Taxes (EBIT)-26,508-25,022
Earnings Before Interest and Taxes (EBITDA)-23,896
 
After tax Income (+$)
Income Before Tax-25,987
Tax Provision-16
Net Income From Continuing Ops-22,438-26,003
Net Income-23,879
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses32,148
Total Other Income/Expenses Net521-2,816
 

Technical Analysis of Evogene
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Evogene. The general trend of Evogene is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Evogene's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Evogene.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.7601 < 1.01 < 1.04.

The bearish price targets are: 0.71 > 0.695 > 0.6473.

Tweet this
Evogene Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Evogene. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Evogene Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Evogene. The current macd is -0.02623655.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Evogene price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Evogene. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Evogene price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Evogene Daily Moving Average Convergence/Divergence (MACD) ChartEvogene Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Evogene. The current adx is 15.86.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Evogene shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Evogene Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Evogene. The current sar is 0.82126501.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Evogene Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Evogene. The current rsi is 39.78. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Evogene Daily Relative Strength Index (RSI) ChartEvogene Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Evogene. The current phase is Oversold in neutral market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Evogene price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Evogene Daily Stochastic Oscillator ChartEvogene Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Evogene. The current cci is -86.69270327.

Evogene Daily Commodity Channel Index (CCI) ChartEvogene Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Evogene. The current cmo is -28.41847672.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Evogene Daily Chande Momentum Oscillator (CMO) ChartEvogene Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Evogene. The current willr is -85.6246985.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Evogene Daily Williams %R ChartEvogene Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Evogene.

Evogene Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Evogene. The current atr is 0.05994762.

Evogene Daily Average True Range (ATR) ChartEvogene Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Evogene. The current obv is 1,192,950.

Evogene Daily On-Balance Volume (OBV) ChartEvogene Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Evogene. The current mfi is 13.00.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Evogene Daily Money Flow Index (MFI) ChartEvogene Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Evogene.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-17STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-05ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Evogene Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Evogene based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.780
Ma 20Greater thanMa 500.838
Ma 50Greater thanMa 1000.816
Ma 100Greater thanMa 2000.781
OpenGreater thanClose0.728
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Evogene with someone you think should read this too:
  • Are you bullish or bearish on Evogene? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Evogene? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Evogene

I send you an email if I find something interesting about Evogene.


Comments

How you think about this?

Leave a comment

Stay informed about Evogene.

Receive notifications about Evogene in your mailbox!